Transgenic coagulation factor XIII defective animal and its use for testing wound healing and bleeding
AssigneeAventis Behring GmbH
InventorsGerhard Dickneite, Hubert Metzner, Gerd Zettlmeissl, Ulrich Grundmann, Richard Lathe, Austin Smith, Meng Li
Life of this patent
Estimating the term…
Abstract
The invention provides a transgenic mouse which is heterozygous or homozygous for an at least partially defective coagulation factor XIII gene.
Claims7
A transgenic mouse whose genome comprises a defective coagulation factor XIII gene, wherein said defective coagulation factor XIII gene comprises the inactivation of the endogenous coagulation factor XIII gene with a DNA construct, wherein said defective coagulation factor XIII gene results in a reduced level of transglutaminase activity which causes impaired wound healing and bleeding disorders in said mouse.
A transgenic mouse whose genome comprises a defective coagulation factor XIII gene comprising a deletion of the active site of exon 7, wherein said defective coagulation factor XIII gene comprises the inactivation of the endogenous coagulation factor XIII gene with a DNA construct, wherein said defective coagulation factor XIII gene results in a reduced level of transglutaminase activity.
Dependencies are inferred from the claim text.